4,700 Shares in Becton, Dickinson and Company $BDX Bought by Stonebridge Capital Management Inc.

Stonebridge Capital Management Inc. bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 4,700 shares of the medical instruments supplier’s stock, valued at approximately $711,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. Auto Owners Insurance Co lifted its stake in Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after acquiring an additional 40,528,680 shares during the period. BlackRock Inc. acquired a new stake in shares of Becton, Dickinson and Company in the second quarter worth $3,721,533,000. Wellington Management Group LLP increased its holdings in Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after buying an additional 5,174,944 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Becton, Dickinson and Company by 23,219.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after buying an additional 4,137,888 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at about $734,321,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.2%

Shares of NYSE:BDX opened at $190.22 on Thursday. The company has a 50 day moving average of $164.35 and a 200-day moving average of $160.49. The firm has a market cap of $52.41 billion, a P/E ratio of 57.30, a P/E/G ratio of 13.38 and a beta of 0.19. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $193.07. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BDX. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Piper Sandler upped their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price on the stock. The Goldman Sachs Group cut their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Finally, Barclays raised their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $185.67.

Insiders Place Their Bets

In related news, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 11,704 shares of company stock worth $1,963,618. Corporate insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.